Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,294Revenue (TTM) $M191Net Margin (%)-97.7Altman Z-Score2.4
Enterprise Value $M2,224EPS (TTM) $-1.6Operating Margin %-65.6Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.0Pre-tax Margin (%)-101.7Higher ROA y-yN
Price/Book4.410-y EBITDA Growth Rate %--Quick Ratio3.1Cash flow > EarningsY
Price/Sales12.95-y EBITDA Growth Rate %-45.5Current Ratio3.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-18.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-29.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M119ROIC % (ttm)-30.9Gross Margin Increase y-yY

Gurus Latest Trades with XON

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

XON is held by these investors:



XON: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KIRK RANDAL JCEO, 10% Owner 2016-12-13Buy34,606$28.9-25.71view
LIFFMAN JOEL DSVP, Finance 2016-12-12Buy8,500$28.62-24.98view
Hassan FredDirector 2016-12-01Buy6,900$29.02-26.02view
Nimrodi NirSVP-Corporate Development 2016-08-29Buy4,000$26.12-17.8view
KIRK RANDAL JCEO, 10% Owner 2016-05-13Buy41,830$23.92-10.24view
KIRK RANDAL JCEO, 10% Owner 2015-12-11Buy124,475$29.85-28.07view
KIRK RANDAL JCEO, 10% Owner 2015-12-07Buy237,525$30.69-30.04view
Krishnan Krish SCOO 2015-12-04Sell20,900$35.66-39.79view
Krishnan SumaSVP--Product Development 2015-12-04Sell20,900$35.66-39.79view
KIRK RANDAL JCEO, 10% Owner 2015-01-27Buy555,556$27-20.48view

Press Releases about XON :

Quarterly/Annual Reports about XON:

News about XON:

Articles On GuruFocus.com
Intrexon Appoints Vinita Gupta, Leading Pharma Executive, to its Board of Directors Apr 27 2017 
ZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call Apr 24 2017 
ZIOPHARM Oncology to Present Updated Clinical Results of Gene Therapy Candidate Ad-RTS-hIL-12 + Vele Apr 20 2017 
Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussi Apr 19 2017 
Fibrocell to Present at 7th Annual World Orphan Drug Congress USA 2017 and 5th Annual Cell & Gene Th Apr 13 2017 
The Municipality of Santiago de Cali, Colombia, and Oxitec Ltd. Announce Memorandum to Deploy Friend Apr 10 2017 
Intrexon, ZIOPHARM and Merck KGaA, Darmstadt, Germany Advancing Next-Generation Non-Viral CAR-T Pla Apr 03 2017 
Oxitec's Friendly™ Aedes Achieves 81% Suppression of Wild Aedes aegypti in CECAP/Eldorado, Pira Mar 31 2017 
ZIOPHARM Announces Successful End-of-Phase 2 Meeting with FDA for Ad-RTS-hIL-12 Gene Therapy in Rec Mar 27 2017 
ZIOPHARM Appoints Amy Trevvett Vice President of Investor Relations and Corporate Communications Mar 27 2017 

More From Other Websites
Intrexon Corp. – Value Analysis (NYSE:XON) : April 27, 2017 Apr 27 2017
Intrexon Appoints Vinita Gupta, Leading Pharma Executive, to its Board of Directors Apr 27 2017
Intrexon Corp. breached its 50 day moving average in a Bullish Manner : XON-US : April 26, 2017 Apr 26 2017
ZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call... Apr 24 2017
ZIOPHARM Oncology to Present Updated Clinical Results of Gene Therapy Candidate Ad-RTS-hIL-12 +... Apr 20 2017
Where Will Intrexon Be in 10 Years? Apr 18 2017
GenVec investor alleges misleading financial disclosures ahead of Intrexon acquisition Apr 14 2017
Fibrocell to Present at 7th Annual World Orphan Drug Congress USA 2017 and 5th Annual Cell & Gene... Apr 13 2017
The Municipality of Santiago de Cali, Colombia, and Oxitec Ltd. Announce Memorandum to Deploy... Apr 10 2017
Intrexon (XON) Down 16.3% Since Earnings Report: Can It Rebound? Apr 03 2017
Intrexon, ZIOPHARM and Merck KGaA, Darmstadt, Germany Advancing Next-Generation Non-Viral CAR-T... Apr 03 2017
Oxitec's Friendly™ Aedes Achieves 81% Suppression of Wild Aedes aegypti in CECAP/Eldorado,... Mar 30 2017
ZIOPHARM Announces Successful End-of-Phase 2 Meeting with FDA for Ad-RTS-hIL-12 Gene Therapy in... Mar 27 2017
ZIOPHARM Appoints Amy Trevvett Vice President of Investor Relations and Corporate Communications Mar 27 2017
3 Stocks That Are Overvalued Mar 22 2017
Jorge Espanha Appointed General Manager of Oxitec do Brasil Mar 17 2017
AquaBounty Technologies, Inc. Results for the year ended December 31, 2016 Mar 16 2017
Intrexon Corp. breached its 50 day moving average in a Bearish Manner : XON-US : March 14, 2017 Mar 14 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)